Content Type: Article

  • Good News for SALT Taxpayers? Supreme Court Overturns Federal Agency Deference

    Good News for SALT Taxpayers? Supreme Court Overturns Federal Agency Deference

    ARTICLE

    Good News for SALT Taxpayers? Supreme Court Overturns Federal Agency Deference

    Jun 28, 2024

    Read time: 5 min

    Key takeaways
    Overview

    On June 28, 2024, in Loper Bright Enterprises v. Secretary of Commerce, the Supreme Court of the United States ruled to overturn its four-decade-old decision in Chevron USA Inc. v. Natural Resources Defense Counsel. While the Loper case addressed deference to administrative agencies under the federal Administrative Procedure Act (APA), its outcome may give state and local taxpayers a better chance of persuading state courts that a tax authority’s interpretation of a tax statute is invalid. This is because many states have relied on the Chevron doctrine when deciding that state administrative procedure acts require deference to an agency action. State courts must now reconsider whether the eradication of Chevron deference at the federal level also applies at the state level.

    BACKGROUND

    Chevron set the standard that federal courts must apply binding deference to a government agency’s interpretation of the law in the absence of a clear answer within the statute itself. Under the Chevron doctrine, if a federal statute was silent or ambiguous on a question of law, and the federal agency charged with enforcing the law had provided an interpretation of that statute, a court was required to defer to the relevant federal agency’s interpretation (even if the court on its own would have reached a different result). For decades, Chevron prevented entities challenging agency action from receiving a balanced review of an issue by courts. The Chevron doctrine has historically presented significant hurdles to plaintiffs, including taxpayers, seeking to challenge actions of federal agencies (such as the Internal Revenue Service).

    But in Loper, the Supreme Court decided that the holding in Chevron is inconsistent with the APA and the historical and constitutional role of the judicial branch, and thus explicitly overturned the Chevron deference standard. This means that, with respect to federal agency interpretations of law, the thumb has been taken off the scale. (Of course, there are still lots of other thumbs on this scale, such as the burden of proof is always on the taxpayer and the preference of judges to favor the state for fiscal reasons, but let’s take a win when we can!).

    EFFECT ON STATE TAX CONTROVERSIES

    The holding in Loper should impact the scope of state court review of state and local tax authority interpretations of law in many circumstances. This is because (a) many states have adopted language substantially similar to the federal APA at issue in Loper and (b) many state courts have specifically cited to Chevron in deferring to a tax authority’s interpretation of the law.

    The potential application to states is clear based on several statements in the Loper opinion. The Supreme Court stated, “Chevron cannot be reconciled with the APA” and “[a]gencies have no special competence in resolving statutory ambiguities. Courts do.” In states that do not have specific statutory provisions providing for deference to a tax authority or specifically delegating authority for interpretation of a specific statute to a tax authority, taxpayers should raise the decision in Loper in an action challenging tax authority regulations. Hearing officers, administrative law judges and judges may be so used to deferring to a state or local tax agency’s interpretation that, unless the issue is specifically raised by a taxpayer, they may never change their ways even if this deference is never specifically referenced in an opinion.

    Taxpayers could see several benefits if the death of the Chevron doctrine is applied at the state and local level. Most importantly, it would eliminate any mandate for absolute deference to a state or local taxing authority’s interpretation of a purportedly ambiguous tax statute, placing taxpayers on a more level playing field in court. It would also give taxpayers more room to argue in court that a statute is ambiguous. While under the Chevron doctrine such an argument could immediately throw a case to the taxing authority, under Loper a court would be required to actually consider what is the best interpretation of a statute, which means that serious consideration of the language will be required.

    CONCLUSION

    Post-Loper, taxpayers should routinely challenge whether a historic tax agency deference standard remains good law in a specific state. Issues such as whether the state uses federal APA language, has historically relied on the Chevron analysis, or employs independent statutory language granting deference to a state tax authority must be considered. At the very least, Loper should make state and local tax authorities that have historically relied on Chevron-style deference at the state level to overpower taxpayers’ legitimate interpretations of a tax statute a little less bold and perhaps a little more willing to discuss and resolve issues with taxpayers.

    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    Michael J. Hilkin

    Partner

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • BIMSCHG Amendment: Significant Simplifications for Onshore Wind Farms

    BIMSCHG Amendment: Significant Simplifications for Onshore Wind Farms

    ARTICLE / CLIENT ALERT

    BIMSCHG Amendment: Significant Simplifications for Onshore Wind Farms

    June 28, 2024

    Read time: 8 min

    Key takeaways
    Overview

    The German Federal Parliament (Bundestag) adopted the reform of the Federal Emission Control Act (Bundes-Immissionsschutzgesetz – “BImSchG“) with the Acceleration Pact for Renewable Energies and Electrolyzers on June 6, 2024, thus implementing a major amendment to emission control law.

    Industry associations consider the Act to Improve Climate Protection in Emission Control, to Accelerate Emission Control Approval Procedures and to Implement EU Law (“BImSchG Amendment“) as a key lever for accelerating approval procedures, particularly for onshore wind farms.

    In the following we provide an overview of the key legislative changes for onshore wind farms.

    1. General Procedural Simplifications

    Overall, the BImSchG Amendment brings various procedural simplifications for all types of installations covered by the BImSchG (in addition to wind farms, e.g. also certain transformer stations and electrolyzers):

    • In the area of digitalization, this concerns not only the strengthening of electronic permit applications (section 10 (1) BImSchG-New), but also the possibility of holding online consultations (section 10 (6) BImSchG-New). In addition, the public announcement of the permit application and the display of the relevant documentation shall largely take place online (section 10 (3) BImSchG-New). The further digitalization of the permitting procedure is primarily intended to make better use of the resources of authorities and applicants and to prevent associated delays.
    • The start and duration of the permitting procedure will also be regulated more clearly. In future, the period of three months (in the simplified procedure) or seven months (in the regular procedure) can only be extended once by three months (see section 10 (6a) BImSchG-New). Previously, an extension was possible several times, which in practice led to considerable delays.
    • The start of the approval period is also determined by law for the first time: According to the new legal requirements, the deadline for approval procedures now begins when the competent authority has not responded within one month of the application being submitted (this deadline can extended once by 2 weeks) or the documents requested for the first time within that deadline have subsequently been submitted by the applicant (see section 7 (1) sentence 4 of the 9th BImSchV-New). This is intended to prevent the start of the deadline being delayed by repeated requests for further documents by the competent authority (as is unfortunately often the case).
    • The BImSchG Amendment stipulates for the first time when permit application documents are complete. According to section 7 (2) of the amended 9th Federal Emission Control Regulation (Neunte Verordnung zur Durchführung des Bundes-Immissionsschutzgesetzes – “9th BImSchV”), documents are now considered complete if they contain information in relation to all legally relevant aspects of the project and enable the authority to examine the application in more detail. From a practical perspective, however, it remains to be seen whether the introduction of this definition will actually lead to a reduction of uncertainties, as the requirements for the documents remain vague. The wording was criticized by industry associations during the consultation phase, but suggestions for improvement were not implemented by the legislator.
    • A public hearing (Erörterungstermin) for objections against onshore wind farms and electrolyzer projects for the production of green hydrogen, shall not take place unless it is explicitly requested by the project developer.
    • For permits granted in the simplified procedure in accordance with section 19 BImSchG (e.g. for wind farms with fewer than 20 wind turbines), it is clarified that the permit must be published at the request of the project developer. Even though this has already been confirmed by the courts, the clarification serves at providing legal certainty. With the public announcement the approval is deemed to have been delivered to concerned third parties as well, therefore, the one-month appeal periods will be set in motion (see section 10 (8) BImSchG).

    2. Project Managers

    The role of project managers will also be strengthened. To this end, a separate provision is being created in the law (section 2b of the 9th BImSchV-New), which defines the assignment and possible list of tasks for project managers.

    In practice, it is often the (insufficient) staffing of the permitting authorities that prolongs the approval process. The increased use of external administrative assistants, who can be deployed unbureaucratically at the project developer’s expense and are authorized to carry out official duties, can effectively counteract such bottlenecks. At the same time, coordination between the parties involved is simplified, as the project manager can take over communication if needed.

    Section 2b of the new 9th BImSchV also stipulates that the assignment and invoicing is generally carried out between the project developer and the project manager. From the authority’s point of view, this reduces the risk of having to bear the costs, which makes the use of a project manager even more attractive for the competent authority.

    3. Repowering

    The BImSchG Amendment also significantly expands the scope of application for repowering regulations in the event of a complete replacement of wind turbines (see section 16b (2) BImSchG-New):

    • Project developers now have twice as long to build the new turbines. Previously, the new turbines had to be constructed within 24 months of the existing plant being dismantled. This period has now been extended to a total of 48 months.
    • The exact choice of location for the new wind turbine is also eased by the BImSchG Amendment. In the future, the distance between the existing turbine and the new turbine may be up to five times the total height of the new turbine; previously, the maximum distance was twice the total height.
    • Furthermore, the so-called delta review will become the standard procedure for repowering projects. This means that generally there will no longer be a comprehensive examination of permissibility; instead, the procedure will be limited to the possible negative deviations between the (already approved) existing turbine and the planned new turbine. Previously, the delta review was only carried out at the request and risk of the project developer and was also content wise limited to certain issues.

    4. Strengthening Preliminary Approvals

    The importance of the preliminary approvals is strengthened. According to the new provisions of section 9 (1a) BImSchG-New, it will no longer be required to assess the impact of the planned overall installation. A preliminary environmental impact assessment (EIA) is therefore no longer required. In practice, the requirement for a preliminary EIA often led to delays in the entire approval process, as the significance of a preliminary positive overall evaluation was regularly assessed differently by project developers and authorities. The resulting uncertainties also had an impact on potential investments in the project at this stage.

    5. Easier Exchange of Turbine Types

    Furthermore, it will also be easier to exchange the type of the wind turbine during the ongoing approval process. Due to the rather long permitting procedure for wind turbines, it often happens that a turbine type is applied for and approved for a project that is already technically outdated when the turbine is built. In the future, according to the new regulation in section 16b (7) BImSchG-New, only the stability and harmful environmental impacts due to noise and adverse effects due to turbulence will be examined if the turbine is only modified slightly. This applies to projects for which the location of the turbine does not change by more than 8 m, the total height does not increase by more than 20 m and the rotor passage is not reduced by more than 8 m (cf. section 16b (7) sentence 3 and (8) BImSchG). In addition, a presumption of approval is introduced for certain type changes: As long as the deviations that are applied for are within the limits set out in section 16b (7) sentence 3 BImSchG, the exchange of the wind turbine is deemed to have been approved after six weeks.

    6. Stricter Requirements for Third-Party Objections

    Finally, permitting procedures will also be streamlined at the level of legal remedies. In principle, legal actions taken by third parties against the approval of a wind turbine already before the current reform had no suspensive effect (see section 63 BImSchG). This means that the developer may continue with the approved project until the approval is either revoked by a court or the suspensive effect is ordered by a court. The BImSchG-Amendment now tightens the requirements for legal actions taken by third parties against the approval in two respects:

    • A one-month period has been introduced for submitting the reasoning for the third-party objection, i.e. if the objection has not been substantiated one month after it has been submitted, the authority shall generally reject it as unfounded (see section 63 (1) sentence 2 BImSchG-New).
    • Secondly, the possibility of preventing the start of construction in a preliminary injunction order has been restricted. In the future, the application to put a suspensive effect on the legal action must be submitted within one month of being notified of the approval.

    In practice, lengthy (legal) procedures often mean that projects are no longer realized, mainly for practical or financial reasons. In the future, the deadline for submitting the reasoning will enable project developers to quickly and reliably assess the risk associated with any objections raised. At the same time, the new regulation on expedited measures means that construction can generally still begin in a timely manner after receiving the approval.

    We will be happy to advise you on all aspects of the energy transition in Germany and on the practical implementation of the BImSchG Amendment.

    Please do not hesitate to get in touch with us!

    You can find more information about our “Energy & Infrastructure” sectore.

    In depth
    Authors
    More insights

  • It’s the plan assets, stupid: Why group medical stop-loss captives and level-funded plans don’t mix

    It’s the plan assets, stupid: Why group medical stop-loss captives and level-funded plans don’t mix

    ARTICLE

    It’s the plan assets, stupid: Why group medical stop-loss captives and level-funded plans don’t mix

    June 27, 2024

    Read time: 5 min

    A question in response to last week’s post on self-funding of employer group health plans assumed that stop-loss coverage under a level-funded plan could be provided under a group captive medical captive. However, it cannot (at least not without first obtaining a prohibited transaction exemption from the US Department of Labor (DOL)). While group medical stop-loss coverage can be structured to avoid the Employee Retirement Income Security Act (ERISA) prohibited transaction rules by scrupulously avoiding contact with ERISA plan assets in the plan’s stop-loss layer, it is not possible to prevent such contact in level-funded products.

    The early years of group captives saw no shortage of handwringing over fundamental compliance issues. For example: Are group captives multiple employer welfare arrangements (MEWAs) (and should they be regulated as such)? To what extent are states free to constrain or restrain their operation? And which state insurance licensing laws apply?

    For the most part, these and other compliance-related questions have been answered, if not completely, then at least substantially so. There is now broad agreement that the group medical stop-loss captive rests on a sound legal and regulatory foundation, which we explained at length in our Special Report. When properly structured, they are not MEWAs; states are free to regulate the stop-loss policy, and the fronting carrier must be licensed in each state in which the captive operates (i.e., where plan participants reside). Critical to their operation, however, is that the group medical stop-loss captive itself does not traffic in plan assets. This means that participant contributions, which are always plan assets, must never be applied to the purchase of stop-loss coverage.

    The treatment of stop loss premiums, and their status as plan assets, are set out in two DOL Advisory Opinions:

    Advisory Opinion 92-02

    A stop-loss insurance policy purchased by an employer sponsoring a self-insured welfare benefit plan to which employees did not contribute is not an asset of the plan if certain conditions are satisfied. These conditions include that the insurance proceeds from the policies are payable only to the plan sponsor, which is the named insured under the policy, and no representations are made that the policy will be used to pay benefits.

    Advisory Opinion 2015-02A

    Where a stop-loss policy is purchased by a plan that includes participant contributions, the stop-loss policy would not be a plan asset if the facts surrounding the purchase of the stop-loss policy satisfies Advisory Opinion 92-02 and if the employer puts in place an accounting system that ensures that the payment of premiums for the stop-loss policy includes no employee contributions. Also, the stop-loss policy must reimburse the plan sponsor only if the plan sponsor pays claims under the plans from its own assets so that the plan sponsor will never receive any reimbursement from the insurer for claim amounts paid with participant contributions.

    In the above-cited Special Report, we provided the following example of how an employer might comply where, as is typically the case, the plan includes participant contributions:

    Employer A hires a third-party administrator to manage its group health plan claims processing, adjudication, and other related tasks and services. The employer establishes an account at Bank X in the name of the employer in which it deposits funds necessary to pay the plan’s obligations. The plan’s third-party administrator has drawing rights on the account that are limited to the payment of plan claims and other plan-related expenses. The employer issues a separate check from its general operating account to cover stop-loss premiums.

    Sponsors of level-funded plans pay a fixed monthly amount that covers claims, fixed costs, stop-loss premiums and administrative expenses. Employer and employee contributions are commingled as a matter of plan design. The plan sponsor’s receipt of any stop-loss policy reimbursements means that the requirement that stop-loss coverage be purchased solely with employer contributions and be separately paid and accounted for is not satisfied. The problem, of course, is that the sponsor’s receipt of plan assets amounts a transfer of assets from a plan to a disqualified person, thereby giving rise to one or more prohibited transactions.

    More insights

  • NYC Employers Take Note: The ‘Workers’ Bill of Rights’ Goes Live July 1

    NYC Employers Take Note: The ‘Workers’ Bill of Rights’ Goes Live July 1

    ARTICLE / CLIENT ALERT

    NYC Employers Take Note: The ‘Workers’ Bill of Rights’ Goes Live July 1

    June 27, 2024

    Read time: 3 min

    Key takeaways
    Overview

    This is the first in a three-part series of alerts focused on what employers need to know about new laws that will be passed or will go into effect this summer in New York. 

    Effective July 1, 2024, all New York City employers must provide their employees with a copy of the New York City Worker Bill of Rights poster.

    In depth

    Which Employers Are Covered?

    This applies to any employer with at least one employee who primarily works within New York City, regardless of whether the work is remote or in-person.

    What Must Be Included in the Posting?

    The NYC Department of Consumer and Worker Protection (DCWP) requires employers to provide a copy of this poster, which includes a QR code that brings employees to the worker bill of rights.

    The law requires that employers:

    1. Post the notice in an area accessible and visible to employees;
    2. Distribute a copy of the notice to each current employee electronically or physically;
    3. Provide the notice to all new employees on or before their first day of work; and
    4. Post the notice online or on a mobile application if such means are regularly used to communicate with employees.

    The city has also published versions of the notice in Spanish, French, Korean and other languages. Employers are required to post all available versions that reflect the primary language(s) spoken by at least 5% of the workforce at a particular location.

    What Are the Penalties for Failing to Comply?

    Employers who fail to comply with the requirements face civil penalties from the DCWP of up to $500 for a first violation, up to $750 for a second violation within a two-year period and up to $1,000 for subsequent violations within a two-year period. The statute is unclear on what counts as a single “violation.” That is, if an employer has one collective instance of failing to provide the notice to 10 employees, it is unclear whether this umbrella oversight constitutes a single violation or 10 distinct violations. In addition, DCWP can order compensatory damages or other relief required to make the employee or former employee “whole.”

    What’s Next?

    Employers should take care to ensure that they provide their employees with the New York City Worker Bill of Rights by July 1.

    Stay tuned for upcoming alerts on New York laws for freelance employees and mandated prenatal leave. If you have questions about the New York City Worker Bill of Rights or other New York employment laws going into effect this summer, please contact your regular McDermott lawyer or Abigail M. Kagan.

    Emily Julve contributed to the development of this On the Subject.

    Authors

    Abigail M. Kagan

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • E for Effort? PI Analysis in Trade Secret Suit Riddled With Errors

    E for Effort? PI Analysis in Trade Secret Suit Riddled With Errors

    ARTICLE

    E for Effort? PI Analysis in Trade Secret Suit Riddled With Errors

    Jun 27, 2024

    Read time: 5 min

    Key takeaways
    Overview

    The US Court of Appeals for the Federal Circuit reversed the granting of a sweeping preliminary injunction (PI) in a trade secret suit against a competitor, finding that the district court’s analysis failed to consider potentially dispositive issues and the requirements of the Defend Trade Secrets Act (DTSA). Insulet Corp. v. EOFlow, Co., Case No. 24-1137 (Fed. Cir. June 17, 2024) (Lourie, Prost, Stark, JJ.) Among other things, the district court:

    • Failed to consider whether the plaintiff’s claims were time-barred.
    • Used an incorrect definition of “trade secret.”
    • Based its irreparable harm analysis on an unsubstantiated fear of a competitor’s potential acquisition of the defendant.
    • Failed to meaningfully assess the balance of harm and the public interest factors.

    Insulet and EOFlow are medical device manufacturers that make insulin pump patches. Insulet began developing its OmniPod product in the early 2000s and launched next-generation models in 2007 and 2013. EOFlow began developing its own insulin pump product, the EOPatch, in 2011 and began work on its second-generation product in 2017. Around the time that EOFlow began developing its second-generation device, four Insulet employees joined EOFlow.

    In early 2023, Medtronic allegedly started a diligence process to acquire EOFlow. Shortly thereafter, Insulet sued EOFlow for trade secret misappropriation, seeking an injunction to bar all technical communications between EOFlow and Medtronic. The district court granted Insulet’s request, finding that Insulet was likely to succeed on its trade secret claim because EOFlow had hired former Insulet employees who retained Insulet’s confidential documents, and Medtronic’s intended acquisition of EOFlow would cause irreparable harm to Insulet. The injunction broadly prevented EOFlow from “manufacturing, marketing, or selling any product that was designed, developed, or manufactured, in whole or in part, using or relying on the Trade Secrets of Insulet.”

    EOFlow appealed the injunction. EOFlow argued that the district court failed to address whether Insulet’s claim was time-barred under 18 U.S.C. § 1836(d) of the DTSA and to consider factors relevant to Insulet’s likelihood of success or meaningfully assess the balance of harm and public interest factors.

    The Federal Circuit first observed that the district court had expressed no opinion regarding EOFlow’s § 1836(d) statute of limitations (SoL) argument, even though Insulet’s compliance with the SoL was a material factor that would significantly impact Insulet’s likelihood of success. This alone constituted an abuse of discretion meriting reversal.

    The Federal Circuit found that even if the district court had addressed the SoL, the injunction was not adequately supported. The Federal Circuit explained that the district court had improperly and broadly defined “trade secret” as “any and all Confidential Information of Insulet,” where “Confidential Information” was defined by the district court to mean any materials marked “confidential” as well as any CAD files, drawings or specifications. The Federal Circuit explained that the district court should have required Insulet to define the allegedly misappropriated trade secrets with particularity. Instead, the district court allowed Insulet to “advance a hazy grouping of information” and stated that “it would be unfair to require at th[at] stage perfection as to the precise number and contours of the trade secrets at issue.” As the Federal Circuit explained, “[i]n order to secure a preliminary injunction, Insulet had to establish the likelihood of its success on the merits for at least one, specifically defined, trade secret. It did not do so.”

    Because the district court relied on an incorrect definition of “trade secret,” it failed to properly assess the factors set forth in the DTSA for determining whether information qualifies as a trade secret:

    • Whether Insulet had taken reasonable measures to keep the alleged trade secrets safe.
    • Whether the information derived independent economic value from not being generally known.
    • Whether the information was readily obtainable through other means.

    For example, while the district court noted that Insulet had marked some documents confidential, it was not clear whether the materials at issue had been marked confidential. Similarly, the OmniPod device was publicly available and could be broken down, but the district court incorrectly concluded that the “mere possibility that something could be reverse engineered without more is not enough to defeat a trade secret claim.” As the Federal Circuit noted, information that can be reverse engineered is not eligible for trade secret protection.

    The Federal Circuit also found that the district court had abused its discretion in its assessment of irreparable harm and the public interest factors. With respect to irreparable harm, the Court reasoned that the alleged harm from Medtronic’s potential acquisition of EOFlow was nothing more than conjecture and an unsubstantiated fear of future harm. The Federal Circuit also took issue with the district court’s sliding scale approach to the PI factors, which required a lesser showing of irreparable harm in view of Insulet’s supposedly strong showing on likelihood of success. Finally, the Federal Circuit found that the lower court did not meaningfully address the public interest factor and instead simply noted that it “saw little impact one way or the other.”

    In view of these deficiencies, the Federal Circuit reversed the grant of PI against EOFLow and remanded for further proceedings.

    Authors
    More insights
    Endnotes

  • FDA v. Alliance for Hippocratic Medicine: Conscience Rights Implications for Healthcare Providers

    FDA v. Alliance for Hippocratic Medicine: Conscience Rights Implications for Healthcare Providers

    ARTICLE / REPORT

    FDA v. Alliance for Hippocratic Medicine: Conscience Rights Implications for Healthcare Providers

    June 27, 2024

    Read time: 3 min

    Overview

    The Supreme Court of the United States’s (SCOTUS’s) unanimous decision in Food and Drug Administration v. Alliance for Hippocratic Medicine (FDA v. AHM) on June 13, 2024, articulated a much more absolute view of the protections federal law affords to individual healthcare provider personnel to refuse to participate in the provision of certain healthcare for personal conscience reasons than has ever previously been articulated in the text, legislative history or judicial interpretation of the relevant federal statutes. That aspect of SCOTUS’s decision may lead to a significant uptick in the number of conscience-based opt-out requests that healthcare provider organizations receive from members of their workforces (e.g., physicians, nurses), while simultaneously making each such request more difficult to address without significant cost or liability exposure.

    All organizations that employ, or independently contract with, individual workers to provide any type of healthcare services that are likely to generate conscience-based objections should become familiar with this new articulation of the scope of individual conscience-based opt-out rights and work together with knowledgeable counsel on how to handle such requests when they arise. As detailed in this report, it remains to be seen how this recent articulation will interact with more established federal laws that address the balance between individual rights and employer burdens.

    In depth
    Tabs

    Sumaya Noush

    Partner

    Chicago

    More insights
    Endnotes

  • Private Fund Managers Alert: New Filing Deadlines and Current Regulatory Focus Areas

    Private Fund Managers Alert: New Filing Deadlines and Current Regulatory Focus Areas

    ARTICLE / CLIENT ALERT

    Private Fund Managers Alert: New Filing Deadlines and Current Regulatory Focus Areas

    June 27, 2024

    Read time: 6 min

    Key takeaways
    Overview

    Private fund managers face several new filing deadlines in the coming months due to recently adopted and amended rules by the US Securities and Exchange Commission (“SEC”) and other regulatory agencies. Preparing for these filings may involve resolving interpretive issues to determine filing requirements and content, as well as updating policies and procedures to ensure accuracy and timeliness. This Alert also highlights new and ongoing focus areas of the SEC’s Division of Enforcement and Division of Examinations to assist managers in evaluating updates to their compliance programs.

    Filing Deadlines for New and Amended Rules

    Below we list key filing deadlines for new and amended rules impacting private fund managers in 2024 and early 2025.

    • Form N-PX – Starting on Aug. 31, 2024, Form 13F filers will be required to disclose their proxy votes on executive compensation matters, otherwise called “say-on-pay” votes, annually on Form N-PX. See Schulte’s Form N-PX Alert.
    • Schedule 13G – The new quarterly initial filing and amendment deadlines for Schedule 13G begin Sept. 30, 2024. Amendment filings for all filers and initial filings for Rule 13d-1(b) and Rule 13d-1(d) filers will now be required 45 days after the end of each calendar quarter (rather than calendar year). See Schulte’s 13G/13D Alert.
    • Corporate Transparency Act (“CTA”) – On Jan. 1, 2024, the Beneficial Ownership Information Reporting Rule (“BOI Rule”) implementing the CTA became effective, requiring certain legal entities formed or registered to do business in the US that are not otherwise exempt (each, a “Reporting Company”) to file a beneficial ownership information report (“BOI Report”) with the US Department of the Treasury’s Financial Crimes Enforcement Network. Under the BOI Rule, Reporting Companies in existence prior to Jan. 1, 2024, must file their initial BOI Reports on or before Jan. 1, 2025. Reporting Companies formed or registered to do business in the US during calendar year 2024 are required to file a BOI Report within 90 calendar days of the formation or registration becoming effective. Notably, Reporting Companies formed or registered to do business in the US on or after Jan. 1, 2025, will be required to file a BOI report within 30 calendar days of the formation or registration becoming effective. See Schulte’s CTA Alert.
    • Short Position Reporting – SEC Rule 13f-2 requires institutional investment managers to report certain equity security short positions to the SEC on new Form SHO. Form SHO filings are due 14 calendar days after the end of each calendar month in which an institutional investment manager has a reportable position, with the first Form SHO filing due no later than Feb. 14, 2025. While Form SHO filings will be treated as confidential, the SEC plans to publish aggregated data derived from Form SHO submissions approximately 14 days after each filing deadline. See Schulte’s Short Reporting Alert.
      • This rule is currently being challenged by several industry groups in the United States Court of Appeals for the Fifth Circuit.
    • Form PF – Amended Form PF, which the SEC and Commodity Futures Trading Commission significantly overhauled earlier this year, will be effective March 12, 2025. The industry is seeking guidance from the SEC regarding the date of the first filing on the amended Form PF since the effective date falls intra-quarter. Notwithstanding this fact, and absent additional clarity from the SEC, private fund managers should be working toward ensuring readiness for reporting on amended Form PF no later than May 31, 2025 (covering Q1 2025). See Schulte’s Form PF Alert.
      • As a reminder, the Form PF current reporting amendments already went into effect in December 2023 and require, among other things, that large hedge fund advisers to qualifying hedge funds file a report within 72 hours of certain enumerated triggering events. See Schulte’s Form PF Current Reporting Alert.

    Recent Enforcement and Examination Activity

    The SEC’s Division of Enforcement and Division of Examinations continue to focus their attention on private fund managers. Expect to see many enforcement cases charging advisers with the use of off channel communication platforms before the SEC fiscal year-end on Sept. 30. These cases will include a range of private fund managers, including large private equity firms, investment advisers with affiliated broker-dealers, as well as several smaller hedge funds. We also anticipate, based on recent public enforcement cases and sweeps, an ongoing focus on managers touting their adoption of artificial intelligence, potential violations of the Whistleblower Protection Rule,[1] compliance with Schedule 13D/G and Section 16 reporting obligations and the relationships and communications between private funds and activist long/short publishers. For its part, the Division of Examinations remains active in its review of private fund managers’ compliance programs in these and other areas detailed in its 2024 Priorities. And, while SEC officials have indicated that the proposed Predictive Analytics Rule and proposed Safeguarding Rule require further development by SEC staff, their public statements as well as enforcement and examination activity reinforce that the SEC staff can leverage existing rules to target these areas, including AI and crypto custody issues.  

    Authored by Christopher S. Avellaneda, William J. Barbera, Allison Scher Bernbach, Michael S. Didiuk, Melissa G.R. Goldstein, Kelly Koscuiszka, Adriana Schwartz, Craig S. Warkol, Derek N. Lacarrubba and Malik Rollins.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See Schulte’s Whistleblower Alert.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2024 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Christopher S. Avellaneda

    Partner

    New York – 919 Third Avenue

    Allison Scher Bernbach

    Partner

    New York – One Vanderbilt Avenue

    William J. Barbera

    Partner

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    More insights

  • Changes to ERISA’s QPAM Exemption and Fiduciary Rule

    Changes to ERISA’s QPAM Exemption and Fiduciary Rule

    ARTICLE / CLIENT ALERT

    Changes to ERISA’s QPAM Exemption and Fiduciary Rule

    June 26, 2024

    Read time: 20 min

    Key takeaways
    Overview

    In recent weeks, the US Department of Labor (“DOL”) has taken significant regulatory and administrative actions affecting how investment advisers manage and advise employee benefit plans subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and individual retirement accounts (“IRAs”). In early April, the DOL issued final amendments to its “Qualified Professional Asset Manager” (“QPAM”) Exemption, a prophylactic prohibited transaction class exemption utilized by investment advisers managing assets of ERISA plans and IRAs. The DOL followed up in late April with a new fiduciary rule that expands the definition of who is or becomes an ERISA fiduciary by providing investment advice with respect to ERISA plans and IRAs (“New Fiduciary Rule”), along with amendments to related prohibited transaction exemptions.

    The QPAM Exemption has been amended by the DOL several times since it became effective in 1984; however, the new amendments (“QPAM Amendments”), which became effective on June 17, 2024, are some of the most significant changes to the exemption. Those changes may encourage some asset managers to explore other applicable prohibited transaction exemptions.

    The New Fiduciary Rule replaces a rule that was issued in 1975. However, if the New Fiduciary Rule seems familiar, it is because the DOL has been trying to broaden the definition of fiduciary under ERISA since 2010. In fact, the DOL issued a revised fiduciary rule in 2016 that was subsequently vacated in 2018 by the US Court of Appeals for the Fifth Circuit. The New Fiduciary Rule might suffer the same fate as its 2016 predecessor. Fortunately, the New Fiduciary Rule should have minimal impact on asset managers, even if it survives in its current form.

    An appendix to this Alert labeled “Action Items to Address New ERISA Rules” describes certain steps that should be taken to address the QPAM Amendments and the New Fiduciary Rule.

    QPAM Exemption

    If the conditions of the QPAM Exemption are met, a QPAM may cause an ERISA plan or IRA, directly or through a separately managed account, fund-of-one or pooled fund that holds ERISA plan assets – commonly referred to as a “plan asset fund”[1] – to enter into a transaction with “parties in interest” with respect to the plan or plans that have invested in the fund that otherwise would have been prohibited by ERISA. To rely on the QPAM Exemption, with respect to any Plan, various conditions must be satisfied at the time of the transaction, including:

    • Neither the party in interest nor any of its affiliates can have the power to hire or fire the QPAM or to negotiate the terms of the QPAM’s management agreement; however, if the transaction involves a plan asset fund with multiple unrelated plan investors, this requirement is met if no single Plan, when aggregated with all other Plans sponsored by the same employer (or affiliated group of employers), represents 10 percent or more of the fund’s assets;
    • The counterparty cannot be a party in interest with respect to a Plan or Plans of the same employer whose assets constitute 20 percent or more of the QPAM’s total assets under management across all of its funds and accounts;
    • The party in interest cannot be the QPAM itself, or any of its affiliates; and
    • At the time the transaction is entered into (and at the time of any subsequent renewal or modification that requires the consent of the QPAM), the terms of the transaction must be at least as favorable to the Plan as the terms generally available in arm’s-length transactions between unrelated parties.
    QPAM Amendments
    QPAM Independence

    The QPAM Amendments clarify that a QPAM must exercise its own independent judgement with respect to a transaction. A QPAM cannot be hired simply to approve a pre-negotiated deal between the transaction’s parties. Where a QPAM shares investment responsibilities, such as in a sub-advisory relationship, each transaction must clearly identify which entity is exercising control over the transaction and acting as a QPAM (for example, who is acting as the QPAM in connection with entering into a Master ISDA Agreement and who is acting as the QPAM in effecting specific transactions under the Master ISDA Agreement).

    Dollar Thresholds

    Only certain banks, insurance companies and investment advisers are eligible to act as a QPAM. With respect to an investment adviser, the adviser must be registered under the Investment Advisers Act of 1940 and meet dollar thresholds imposed by the exemption for total client assets under its management and control (“AUM”), measured as of the last day of its most recent fiscal year, and shareholders’ or partners’ equity (or the payment of the investment adviser’s liabilities must be guaranteed by certain entities having equity equal to the threshold imposed by the exemption). As shown in the table below, the QPAM Amendments increase those dollar thresholds over the next six years:

    After 2030, the DOL will make subsequent annual adjustments to reflect inflation.

    Disqualification

    An asset manager – whether an investment adviser, bank or insurance company – cannot act as a QPAM if, within the 10 years prior to a transaction, the asset manager or any of its “affiliates” (discussed below) has been convicted of, or released from prison as a result of a conviction in respect of, a broad range of felonies involving the misuse of money (e.g., theft, extortion, forgery, misappropriation of funds). The QPAM Amendments clarify and expand the types of convictions and other misconduct that disqualify an asset manager from utilizing the QPAM Exemption regardless of whether the asset manager was directly involved in, or had any knowledge of, the “bad acts.”

    The QPAM Amendments generally define a “Criminal Conviction” as a conviction in a US or state court in respect of certain crimes,[2] as well as a criminal conviction by a foreign court, regardless of how the applicable foreign jurisdiction classifies the crime (e.g., felony, etc.), if the foreign crime is substantially equivalent to one of the US criminal offenses listed in the QPAM Exemption. However, a conviction in a foreign country that has been identified as a “foreign adversary” by the US Department of Commerce is excluded as a Criminal Conviction under the QPAM Exemption.

    In addition to actual convictions, the QPAM Amendments disqualify an asset manager from serving as a QPAM if the asset manager or any of affiliate has engaged in a new category of misconduct, referred to as “Prohibited Misconduct.” In general, Prohibited Misconduct includes entering into a non-prosecution (“NAP”) or deferred prosecution agreement (“DPA”) on or after June 17, 2024, with a US federal or state prosecutor’s office or regulatory agency, where the factual allegations that form the basis for the NAP or DPA would have constituted a Criminal Conviction if they were successfully prosecuted. Prohibited Misconduct also includes conduct that is determined in a final judgment or court-approved settlement by a US or state criminal or civil court, in a proceeding brought by certain US (including the DOL) or state authorities that involves:

    • Engaging in a systematic pattern or practice of conduct that violates the conditions of the OPAM Exemption in connection with otherwise non-exempt prohibited transactions;
    • Intentionally engaging in conduct that violates the conditions of the QPAM Exemption in connection with otherwise non-exempt prohibited transactions; or
    • Providing materially misleading information to the DOL or certain other US or state authorities in connection with the conditions of the QPAM Exemption.

    Importantly, the QPAM Exemption defines an “affiliate” broadly, and in a manner that, with respect to any asset manager, would include: (1) any person directly or indirectly through one or more intermediaries, controlling, controlled by, or under common control with the asset manager; (2) any director of, relative of or partner in, the asset manager; (3) any corporation, partnership, trust or unincorporated enterprise of which such person is an officer, director, or is a five percent or more partner or owner; and (4) any employee or officer of the asset manager who (a) is a highly compensated employee or officer (earning 10 percent or more of the yearly wages of the asset manager); or (b) has direct or indirect authority, responsibility, or control regarding the custody, management or disposition of plan assets. In turn, the QPAM Exemption defines “control” as the power to exercise a controlling influence over the management or policies of a person other than an individual. Accordingly, an “affiliate” of an asset manager includes parent entities and subsidiaries and may include a portfolio company controlled directly by the asset manager or indirectly through a fund managed by the asset manager.

    If an asset manager becomes disqualified from acting as a QPAM because of a Criminal Conviction or Prohibited Misconduct, the asset manager will be unable to rely on the QPAM Exemption; however, the asset manager may be able to rely on the QPAM Exemption solely with respect to its existing Plan clients during a one-year transition. For the one-year transition period to apply, the asset manager must notify, in writing, the DOL and each of its Plan clients of the facts surrounding the conduct that disqualified the asset manager. In particular, the notice must provide an objective description of the facts and circumstances of the Criminal Conviction or Prohibited Misconduct that contains sufficient detail to fully inform the applicable Plan’s fiduciaries (in the case of a plan asset fund, the fiduciaries of the Plans invested in the fund) of the nature and severity of the conduct in order to enable the fiduciary to satisfy its duties with respect to hiring, monitoring, evaluating and retaining the asset manager in a non-QPAM capacity.

    The asset manager must also notify its Plan clients that, during the one-year transition period, the asset manager:

    • Will not restrict the ability of the Plan client to terminate or withdraw from its arrangement with the asset manager (which includes redeeming from a plan asset fund);
    • Will not impose any fees, penalties or charges on the Plan client in connection with the process of terminating or withdrawing (other than certain fees designed to protect against abusive investment practices or protect other investors in plan asset funds);
    • Will indemnify the Plan client for actual losses (including losses and related costs arising from unwinding transactions with third parties and transitioning to a different asset manager), resulting from the current asset manager becoming disqualified; and
    • Will not employ or knowingly engage any individual that participated in the Criminal Conviction or Prohibited Misconduct.

    DOL Notice

    The QPAM Amendments also impose new notice and recordkeeping requirements. To qualify as a QPAM, an asset manager must notify the DOL by sending an email to QPAM@dol.gov providing the legal name of each entity relying on the QPAM Exemption and any name under which the QPAM may be operating. A QPAM must send its email notification to the DOL within 90 calendar days after relying on the QPAM Exemption or changing its legal or operating name. An asset manager that is relying on the QPAM Exemption as of the effective date of the QPAM Amendments must send its email notice to the DOL by no later than Sept. 15, 2024.

    Absent a change to its legal or operating name or ceasing to rely on the exemption, the email notification must be made only once and need not name any particular plan or fund, nor any specific transaction or any particular point in time when the asset manager is engaging in transactions in reliance on the QPAM Exemption. An asset manager that inadvertently fails to meet the deadline for sending its email notice to the DOL may cure its failure by sending the email notice within 180 calendar days; however, the late notice must include an explanation for failing to meet the 90 calendar day deadline. A QPAM may also notify the DOL at any time if it is no longer relying upon the QPAM Exemption.

    Recordkeeping

    The QPAM Amendments require that, with respect to any transaction for which a QPAM relied on the QPAM Exemption, the QPAM must maintain records to show that the conditions of the QPAM Exemption have been met. The records must be reasonably available for inspection, for a period of six years, at the QPAM’s customary location during normal business hours, by constituents of Plan clients, consisting of:

    • Any authorized employee of the DOL or the Internal Revenue Service or another US or state regulator;
    • Any fiduciary of an ERISA plan or IRA managed by the QPAM or that has invested in a plan asset fund managed by the QPAM;
    • Any contributing employer and any employee organization whose members participate in an ERISA plan managed by the QPAM or that has invested in a plan asset fund managed by the QPAM; or
    • Any participant or beneficiary of an ERISA plan or IRA managed by the QPAM or that has invested in a plan asset fund managed by the QPAM.

    In the preamble to the QPAM Amendments, the DOL stated that the new recordkeeping requirements are not intended to require transaction by transaction recordkeeping. Instead, the DOL indicated that the requirement should be satisfied, for example, if records are retained that demonstrate that the asset manager met the QPAM Exemption’s net worth and assets under management conditions at the time of a particular transaction and that the asset manager was unrelated and independent from the applicable parties in interest involved in the transaction (discussed above). In addition, a QPAM is not required to disclose to Plan constituents (except for government authorities) its trade secrets, commercial or financial information or records regarding any fund in which the applicable Plan client is not invested. Nevertheless, a QPAM must explain, in a written notice to a requesting Plan constituent, the reason why the QPAM has not provided information. If the new recordkeeping requirements are not satisfied, only the QPAM, and not other parties, may be subject to a civil penalty assessed under ERISA or excise taxes imposed under the Internal Revenue Code of 1986, as amended. However, the loss or destruction of required records due to circumstances beyond the control of the asset manager will not cause the applicable transaction to lose its reliance on the QPAM Exemption.

    Potential Use of Other Prohibited Transaction Exemptions

    While the QPAM Exemption has long served as the “gold standard” of ERISA exemptions, other prohibited transaction exemptions now exist to cover most, if not all, of the transactions covered by the QPAM Exemption. Given the additional requirements imposed under the QPAM Exemption, we anticipate that asset managers will consider shifting their reliance from the QPAM Exemption to those alternative exemptions, such as ERISA’s “Service Provider Exemption” (also referred to as “408(b)(17)” – the applicable section of ERISA) and “Necessary Services Exemption” (also referred to as “408(b)(2)” – the applicable section of ERISA).

    New Fiduciary Rule

    The New Fiduciary Rule expands the category of persons who are considered a fiduciary by providing investment advice to a “Retirement Investor” – a category of investor that covers (1) any ERISA plan as well as its participants (and participants’ beneficiaries) and fiduciaries and (2) any IRA as well as the IRA owner (and IRA owner’s beneficiaries) and the IRA’s fiduciaries.

    The New Fiduciary Rule addresses the circumstances under which a person who does not exercise investment discretion over plan assets will be considered a fiduciary as a result of providing an investment recommendation to a Retirement Investor. The New Fiduciary Rule refers to such a fiduciary as an “investment advice fiduciary” and focuses on investment recommendations regarding:

    • The advisability of acquiring, holding, disposing of, or exchanging, securities or other investment property, or an investment strategy;
    • How securities or other investment property should be invested after the securities or other investment property are rolled over, transferred, or distributed from an ERISA plan or IRA;
    • The management of securities or other investment property, including recommendations on investment policies or strategies, portfolio composition, selection of other persons to provide investment advice or investment management services, selection of investment account arrangements (e.g., account types such as brokerage versus advisory) or voting of proxies; and
    • The rolling over, transferring, or distributing assets from an ERISA plan or IRA, including recommendations as to whether to roll over, transfer or take a distribution and the amount, the form and the destination of such a rollover, transfer or distribution.

    An investment recommendation, alone, will not give rise to fiduciary status. Under the New Fiduciary Rule, a person will be an Investment Advice Fiduciary with respect to a Retirement Investor only if: (1) the person, either directly or through affiliates, makes professional investment recommendations to investors on a regular basis as part of their business and (2) the investment recommendation to the Retirement Investor:

    • Is provided for a fee or other compensation, direct or indirect;
    • Is made under circumstances that would indicate to a reasonable investor in like circumstances that the recommendation;
      • Is based on review of the Retirement Investor’s particular needs or individual circumstances,
      • Reflects the application of professional or expert judgment to the Retirement Investor’s particular needs or individual circumstances, and
      • May be relied upon by the Retirement Investor as intended to advance the Retirement Investor’s best interest.

    Alternatively, even if the criteria above is not met, a person will be considered a fiduciary under the New Fiduciary Rule by representing or acknowledging to the Retirement Investor that it is acting as an ERISA fiduciary. In contrast, however, the New Fiduciary Rule expressly provides that written disclaimers, alone, may be ineffective in avoiding fiduciary status as an Investment Advice Fiduciary.

    Importantly, the New Fiduciary Rule makes clear that marketing and sales communications will not give rise to fiduciary status under ERISA. As an example, the New Fiduciary Rule provides that a recommendation to a Retirement Investor, made in connection with marketing, to purchase a particular investment or pursue a particular investment strategy will not give rise to an ERISA fiduciary relationship if the other conditions are not met and no inconsistent representation or acknowledgment is made indicating that the recommendation is being made by an ERISA fiduciary.

    Action Items to Address New ERISA Rules

    QPAM Exemption

    • If a fund is designed to be a non-plan asset fund (i.e., it does not hold ERISA “plan assets”), no action is necessary. The fund is not a plan asset fund, the fund’s transactions are not subject to ERISA and, therefore, the asset manager does not rely on the QPAM Exemption (or any other prohibited transaction exemption) with respect to any aspect of the management of the fund.
      • No action is necessary even if the manager has agreed in a side letter or other document that it would be a QPAM if the fund were to become a plan asset fund unless the fund actually becomes a plan asset fund.
    • If an asset manager reserves the right in governing fund documents to allow a fund to become a plan asset fund (a “Springing QPAM”), but the fund is not currently a plan assets fund and the manager does not foresee it becoming a plan asset fund, consideration should be given to revising the fund’s governing documents to remove the ability of the fund to become a plan asset fund.
      • If a fund is not currently a plan asset fund, but such flexibility is desired, consider adopting an internal process that must be followed prior to the fund becoming a plan asset fund due to inflows or outflows. No filing of a QPAM notice with the DOL is necessary if the fund is not currently a plan asset fund.
    • With respect to any plan asset fund (including any plan asset fund of funds) or any separately managed account or fund-of-one of an ERISA plan:
      • To comply with the QPAM Exemption’s new DOL notice requirement, send the required email to the DOL, addressed to QPAM@dol.gov, by Sept. 15, 2024. The email need only include the following statement:
        • This email serves to notify the US Department of Labor that [insert name of asset manager and any names under which the asset manager may be operating] intends to rely on Prohibited Transaction Exemption 84-14 as a “QPAM.”
      • Review applicable trading documents and prime brokerage agreements to determine whether they require that transactions be effected solely in compliance with the QPAM Exemption or, whether they permit use of the Service Provider Exemption as an alternative. If no alternative language is included, consider renegotiating the trading documents to permit the asset manager to rely on the Service Provider Exemption.
      • Determine what steps, if any, need to be undertaken before Dec. 31, 2024 to ensure that the manager satisfies the new assets under management and shareholder’s/partner equity thresholds and prepare a balance sheet to be used to show such compliance.
    • With respect to clients that are neither ERISA plans or IRAs nor funds designed not to be plan assets funds, review all investment management agreements and side letters to determine whether the manager has committed contractually to qualifying as a QPAM. Such a commitment is sometimes agreed to by a manager with respect to a governmental plan investor and/or a Taft Hartley (i.e., union) pension plan. Typically, those provisions only require the asset manager to be subject to the standard of care and do not mention QPAM.
    • With respect to any asset manager relying on, or who may rely on, the QPAM Exemption, adopt procedures to ensure that, in addition to developments affecting the asset manager itself, any five percent owner of the asset manager or any “affiliate” of the asset manager provides to the asset manager advance notice of any developments (i.e., a Criminal Conviction or Prohibited Misconduct) by such five percent owner or affiliate that could result in the disqualification of the asset manager to act as QPAM.
      • The procedures should be communicated to each five percent owner and affiliate and considered in connection with the transaction involving the asset manager, any of its affiliates or managed funds.
    • Adopt written procedures to ensure that appropriate due diligence is conducted before there is a purchase or sale of equity in an asset manager relying on the QPAM Exemption or in the parent of such asset manager to determine if such transaction could result in the disqualification of the asset manager to act as QPAM, regardless of whether the asset manager is currently acting as a QPAM.

    New Fiduciary Rule

    • Analyze and inventory which services, if any, are provided to investors in the capacity of an ERISA fiduciary.
      • If multiple investment services are provided to a particular client in the capacity of both an ERISA (or IRA) fiduciary and non-ERISA (or non-IRA) fiduciary, each service should be identified and inventoried.
      • Implement procedures to maintain the distinction between ERISA (or IRA) fiduciary services and non-ERISA (or non-IRA) fiduciary services for the same client.
    • Consider adopting a written policy or guidelines and train client-facing personnel regarding appropriate client communications – whether written or verbal – to help prevent unintended fiduciary status.
      • Where multiple investment services are provided to a particular investor, the guidelines should describe appropriate procedures to help maintain the distinction between the ERISA fiduciary and non-ERISA fiduciary services.

    Authored by David M. Cohen and Ian L. Levin.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] For simplicity, any reference in this Alert to the term “Plan” will generally mean plans subject to ERISA’s fiduciary rules, IRAs, separately managed account and funds-of-one of ERISA plans or IRAs and plan asset funds.

    [2] In general, the crimes include a felony involving abuse or misuse of such person’s plan position or employment, or position or employment with a labor organization, any felony arising out of the conduct of the business of a broker, dealer, investment adviser, bank, insurance company or fiduciary, income tax evasion, any felony involving the larceny, theft, robbery, extortion, forgery, counterfeiting, fraudulent concealment, embezzlement, fraudulent conversion or misappropriation of funds or securities.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2024 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    David M. Cohen

    Partner

    New York – 919 Third Avenue

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    More insights

  • Louisiana MGA Legislation: A Sign of Heightened Scrutiny?

    Louisiana MGA Legislation: A Sign of Heightened Scrutiny?

    ARTICLE / CLIENT ALERT

    Louisiana MGA Legislation: A Sign of Heightened Scrutiny?

    June 25, 2024

    Read time: 7 min

    Key takeaways
    Overview

    Louisiana recently amended its statutes regulating managing general agents (MGAs). Certain of the amendments conform Louisiana law to the National Association of Insurance Commissioners MGA Model Act (NAIC Model) adopted in nearly all US states or are mere technical changes. However, a few changes expand Louisiana law beyond the NAIC Model, most notably in imposing new financial reporting obligations and other requirements on MGAs and their insurer partners. These amendments go into effect on August 1, 2024.

    Background, including recent press coverage, for the Louisiana legislation (aka House Bill 672) suggests the measure relates to a recent series of insolvencies among Louisiana-domiciled insurers that rely upon affiliated MGAs as a business model. However, the amendments fall within the scope of existing law and thus have wider applicability. MGAs, managing general underwriters (MGUs), program administrators, re/insurers and investors should be aware of these changes in Louisiana and be mindful of the potential for increased regulatory, commercial and rating agency scrutiny as the MGA sector continues to grow.

    In depth

    Current Louisiana Law

    Like the NAIC Model, Louisiana’s existing MGA statutes require a license to “act in the capacity of an MGA” (i) “with respect to risks located in [Louisiana] for an insurer licensed in [Louisiana]” or (ii) “representing an insurer domiciled in [Louisiana].” La. R.S. 22:1623(A). To “act in the capacity of an MGA in [Louisiana]” a person must be licensed as a property and casualty producer and be appointed as a producer for the applicable insurer(s) and register as an MGA and pay a fee in Louisiana. La. R.S. 22:1623. (See Application for New or Renewal MGA Registration, revised December 2022.)

    Essentially tracking the NAIC Model, Louisiana defines an MGA as:

    [A]ny person who manages all or part of the insurance business of an insurer … and acts as an agent for such insurer whether known as a managing general agent, manager, or similar term, who, with or without the authority, either separately or together with affiliates, produces, directly or indirectly, and underwrites an amount of gross direct written premium equal to or more than five percent of the policyholder surplus as reported in the last annual statement of the insurer in any one quarter or year together with one or more of the following:

    (i) Adjusts or pays claims in excess of an amount determined by the commissioner.

    (ii) Negotiates reinsurance on behalf of the insurer.

    La. R.S. 22:1622(4)(a).

    “Insurer” is defined as “any person duly licensed in this state as an insurer ….” Id. at 22:1622(3). In Directive 127 (revised and reissued on August 31, 2020) the Louisiana Department of Insurance (LDI) Commissioner determined the claims paying authority trigger in La. R.S. 22:1622(4)(a)(i) above is $10,000.

    An insurer using an MGA to write “more than five percent of its policyholder surplus” currently must “provide financial data by an independent examiner concerning that insurer’s book of business which is in question and is handled by that MGA upon request, and the insurer shall have on file an independent financial examination, in a form acceptable to the commissioner, of each MGA with which it has done business.” La. R.S. 22:1625(A).

    Current law also provides that “[a]n MGA may be examined as if it were the insurer.” La. R.S. 22:1626.

    Current law also requires an MGA to “reimburse the insurer or the rehabilitator or liquidator of the insurer for any losses incurred by the insurer caused by a violation of [the MGA law] committed by the MGA.” Id. at 22:1627(A)(3). This is arguably broader than the NAIC Model, which expressly authorizes the Commissioner or receiver to maintain a civil action for recovery of damages. NAIC Model Section 7B.

    House Bill 672

    In addition to incorporating certain NAIC Model provisions not presently included in existing law, House Bill 672 imposes expansive obligations on MGAs and insurers that transact in this fashion.

    Quarterly Reports

    An MGA must submit quarterly an “account report” to each insurer with whom the MGA has a contract and include in the report, as applicable, a statement of various items, including written, earned and unearned premiums; losses and loss adjustment expenses; an outline of other expenses on a prescribed form; and management fees. La. R.S. 22:1628(A). These should be standard terms in any MGA agreement in our experience, though the timing/requirement of reporting may vary by agreement.

    Adverse Development Regulatory Notices

    An MGA must notify the LDI within 30 days of various events (or submit a single annual report “if the MGA routinely operates above the [below established] limits”):

    • A balance owed to an insurer of $1 million or 10% of the insurer’s policyholder surplus exceeds 90 days
    • Balances due for more than 60 days from a property and casualty agent/MGA exceed $500,000
    • Claims authority is withdrawn
    • A loss fund account is greater than $100,000 more than the amount needed to pay losses and loss adjustment expenses expected to be paid on the insurer’s behalf within the next 60 days
    • The MGA agreement is terminated.

    Audited Financials

    In addition to the current requirement to provide to the LDI Commissioner, upon request, financial data by an independent examiner concerning the MGA business at issue, an insurer using an MGA will now be required to have on file an independent audited financial report of each MGA (similar to the NAIC Model, which requires such a report for the two most recent fiscal years showing the MGA’s positive net worth), which also must be submitted to the Commissioner upon request. Such report must include the opinion of an independent certified public accountant regarding the recent annual financial position of the MGA and certain financial information. La. R.S. 22:1625(A).

    MGA Examinations

    The new law expressly authorizes the Commissioner to examine, and charge the MGA to examine, the MGA’s financial condition. La. R.S. 22:1626(B), (C).

    Ban on Persons Involved in a Prior Insurer Insolvency

    Louisiana will generally prohibit a person from acting as an MGA if they managed a Louisiana-licensed insurer within two years before the insurer became insolvent. La. R.S. 22:1623(E).

    Backdrop for House Bill 672

    Press reports regarding House Bill 672 suggest the measure responds to recent insolvencies among Louisiana-domiciled insurers, which some observers and stakeholders attributed (at least in part) to such insurers’ relationships with affiliated MGAs. These insurers primarily focused on property catastrophe risks, including risks previously insured by the state’s residual market. However, the Louisiana legislation imposes heightened scrutiny beyond the NAIC Model on all MGA relationships regardless of affiliation. Thus, if the press reports are accurate, at least certain portions of House Bill 672 are arguably excessive.

    Although not cited by legislators, LDI or the press, the Louisiana legislation is on trend with increased industry coverage and reporting on the sustained growth, performance and investor interest in the MGA sector (See, e.g., “MGA Valuations and M&A Activity Not a ‘Bubble’” and an AM Best report entitled “Rapidly Increasing MGA Premiums Warrant Greater Oversight.”) The AM Best report’s “Principal Takeaways” include:

    Rapid insurance growth may point to increasing risk if lax underwriting or weaker product design drives the growth….

    A.M. Best expects insurers to perform appropriate due diligence to prevent insurer insolvencies from MGA relationships.

    Increasing ownership of DUAEs by private equity companies mandates greater scrutiny.

    Conclusion

    House Bill 672 is an example of the type of heightened regulatory scrutiny of MGA relationships that can follow adverse – and even positive – market developments.

    By all accounts, the expansion of the MGA/program administrator sector continues to rapidly evolve. The increased focus of de facto regulators such as AM Best, attributed in some instances to apparent/perceived gaps in oversight by insurers who may have “given away the pen” and in other instances to truly rogue MGA operations, only heightens state insurance regulators’ possible sense of urgency to play catch-up. With the nature of regulatory momentum invariably flowing the only way it typically can operate, the prospect of reactive and remedial (and potentially overly prescriptive) legislation and regulations remains no more than an insolvency or rogue MGA away.

    Authors

    H. Michael Byrne

    Partner

    New York – One Vanderbilt Avenue

    Michael R. Halsband

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Right Time for Innovation: Apple Watch Gets Nod From FDA for Device Development Tool

    Right Time for Innovation: Apple Watch Gets Nod From FDA for Device Development Tool

    ARTICLE / CLIENT ALERT

    Right Time for Innovation: Apple Watch Gets Nod From FDA for Device Development Tool

    June 24, 2024

    Read time: 6 min

    Key takeaways
    Overview

    The US Food and Drug Administration (FDA) recently announced its qualification of the Apple Atrial Fibrillation (AFib) History Feature through the Medical Device Development Tools (MDDT) program. The MDDT program is intended to promote innovation and device development by providing medical device sponsors with scientific assessments the FDA will accept for measuring the safety and efficacy of their devices. The Apple AFib History Feature, which uses pulse rate measurements collected by an Apple Watch to measure a wearer’s AFib burden, is the first digital tool qualified by the FDA as part of the MDDT program and reflects the FDA’s increased focus on innovation.

    In depth

    The MDDT Program

    The MDDT program was developed by the FDA to improve predictability and efficiency in medical device development and the regulatory review process. The program achieves this by qualifying tools (i.e., medical device development tools) for measuring the safety and efficacy of medical devices that developers know the FDA will accept. Providing a set of accepted tools that can be used to support the approval of a new medical device promotes innovation by reducing uncertainty in the development process and reducing the need to develop or support the measure used to demonstrate the efficacy and safety of a new device. The FDA hopes the program will also incentivize the development and widespread acceptance of new MDDTs by offering a pathway for tool developers and device sponsors to gain assurance from the FDA that use of the tool will be accepted when used as qualified.

    The FDA qualifies a range of tools through its MDDT program, from computational and animal models to digital health technologies like sensors or wearables. The FDA places MDDTs into three different categories:

    1. Non-Clinical Assessment Models: Non-clinical test models designed to measure or predict important parameters of device effectiveness, performance and safety.
    2. Biomarker Tests: Biomarkers can be important signals of a device’s performance and be used to assess risk and safety concerns and predict patient outcomes. Biomarker tests are designed to measure or detect biomarkers.
    3. Clinical Outcome Assessment: These assessments describe a patient’s own perceptions, functioning or survival and can be collected in clinic or remotely. They may be reported by a patient, a non-clinical observer (e.g., a caregiver or family member), a healthcare provider or through the performance of a task or activity.

    MDDTs must go through a two-phase qualification process. First, in the Proposal Phase, the FDA asks the submitter of a potential MDDT to provide certain information about the tool, the data collection plan for the tool and context of use for the tool. During this phase, the FDA may provide feedback to submitters on their plan to gather supporting evidence for the tool’s qualification.

    Next, during the Qualification Phase, the FDA asks the submitter to provide the evidence and data collected based on the qualification data collection plan developed during the Proposal Phase. Tools that are adequately supported by the collected evidence are qualified as MDDTs in the specific contexts of use supported by the evidence.

    Recently Qualified MDDTs Spotlight Innovation and Usefulness of Wearables in Device Development

    Since 2017, the FDA has qualified 17 MDDTs. Among the three MDDTs added so far this year is the Apple AFib History Feature, which is the first digital MDDT. The tool analyzes the data to identify periods of irregular heartbeats consistent with AFib and estimates the amount of time spent in AFib (the AFib burden) during the past week. The clinical value of assessing the AFib burden has been recognized by both the FDA and medical device developers. The Apple AFib History Feature may be used as a secondary effectiveness endpoint within clinical studies evaluating the safety and effectiveness of cardiac ablation devices but is not intended to replace the findings of primary endpoints for cardiac ablation devices.

    In its qualification of the tool, the FDA observed that collecting valuable clinical data through widely available and familiar wearables could address data acquisition challenges, from patient compliance and potential placebo effects to technical difficulties with collecting certain measures without an implanted device. Device developers across markets are looking for new tools to address data collection challenges and reduce uncertainty in the device approval process. This recent qualification not only illustrates the still unmet tool needs of device developers but also highlights how valuable wearable technologies and sensors can be in addressing this need.

    The qualification of a digital MDDT for use in clinical devices follows closely behind the FDA’s guidance on the use of digital health technologies (DHTs) for data acquisition in clinical studies, which was finalized in December 2023. A DHT is “a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses.” The FDA’s 2023 finalized guidance builds on draft guidance from 2021 and provides recommendations on using DHTs for remote data acquisition in clinical investigations of medical products. The guidance addressed selecting DHTs for use in clinical studies, describing DHTs in regulatory filings, validating DHTs and collecting data for trial endpoints, DHT data retention and protection, managing risks of using DHTs, and the roles of sponsors and investigators related to the use of DHTs. Both the qualification of the first digital tool through the MDDT program and the FDA’s recent guidance on the use of DHTs in clinical studies reflect the need for more convenient and reliable methods for collecting data measuring safety and effectiveness in clinical investigations of new devices and drugs.

    Development of a new tool that addresses existing industry data acquisition challenges can be a valuable source of revenue, as can qualification of a tool in the MDDT program, which can indicate regulator acceptance to customers and investors alike. For more information about MDDTs or about participating in the MDDT program, contact one of the authors or any other member of McDermott’s Food, Drug & Medical Device Regulatory Practice Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Nathan Gray

    Associate

    Washington, DC

    More insights